Clinical Scorecard: Closing the Genomic Gap in Rare Disease
At a Glance
| Category | Detail |
|---|---|
| Condition | Rare Diseases |
| Key Mechanisms | Long-read genomics enhances diagnostic yield by providing complete genomic context. |
| Target Population | Children with rare diseases, particularly those lacking access to genomic testing. |
| Care Setting | Clinical settings across 25 sites in 14 countries. |
Key Highlights
- iHope provides no-cost genomic testing to over 1,000 patients annually.
- Rare diseases affect more than 300 million people globally.
- Long-read sequencing can detect complex structural variants missed by short-read technologies.
- Systemic barriers limit access to genomic testing in many regions.
- Precision therapies require detailed genomic characterization for effective treatment.
Guideline-Based Recommendations
Diagnosis
- Implement long-read whole genome sequencing as a first-line test for suspected rare genetic diseases.
Management
- Utilize comprehensive genomic data to guide precision therapies and connect families to support networks.
Monitoring & Follow-up
- Regularly assess the accessibility and effectiveness of genomic testing across different regions.
Risks
- Inadequate access to genomic testing may delay diagnosis and appropriate management of rare diseases.
Patient & Prescribing Data
Children with suspected rare genetic disorders.
Precision therapies depend on accurate genomic characterization to ensure efficacy.
Clinical Best Practices
- Adopt long-read sequencing to improve diagnostic accuracy.
- Address systemic barriers to enhance access to genomic testing.
- Facilitate connections between patients and clinical support networks.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
